Article
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Molecular cancer therapeutics - 1 Jan 2015
Junttila Melissa R, Devasthali Vidusha, Cheng Jason H, Castillo Joseph, Metcalfe Ciara, Clermont Anne C, Otter Douglas Den, Chan Emily, Bou-Reslan Hani, Cao Tim, Forrest William, Nannini Michelle A, French Dorothy, Carano Richard, Merchant Mark, Hoeflich Klaus P, Singh Mallika
Abstract excerpt
Activating mutations in the KRAS oncogene occur in approximately 90% of pancreatic cancers, resulting in aberrant activation of the MAPK and the PI3K pathways, driving malignant progression. Significant efforts to develop targeted inhibitors of nodes within these pathways are underway and several are currently in clinical trials for patients with KRAS-mutant tumors, including patients with pancreatic cancer. To...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.